Crown Bioscience

NOVEMBER 22, 2024

The field of oncology research demands innovative, multi-dimensional approaches to tackle the complexities of cancer biology, therapeutic responses, and immune interactions. Designed for high-throughput applications, HCI accelerates therapeutic compound screening while uncovering mechanisms of resistance and drug responses.

Compound Screening 52

Compound Screening Research Drugs 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. Acta Cryst. Acta Cryst. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

Broad Institute

JULY 26, 2022

Learn more COVID-19 portals and datasets Broad data scientists and software engineers have developed several portals and datasets to support COVID-19-related research. Learn more Drug Repurposing Hub A curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds.

Compound Screening 52

Compound Screening FDA Approval Engineering RNA 52

KIF1A

AUGUST 28, 2024

Here’s a sneak peek at what’s in store: Upcoming Meetings : Newly Diagnosed Meetup, 3rd Quarter Community Call, & Research Roundtable ASO Study Publication : We’re thrilled to announce the groundbreaking publication of our first-ever ASO study—an incredible milestone for our community!

Therapies 52

Therapies Compound Screening Research Treatment 52

The ChEMBL-og

APRIL 16, 2024

A company research code, or Clinical Trial intervention name, is assigned if no standardised name is available. For virtual parent compounds, progress has been made towards assigning a distinct pref_name (typically based on the FDA GSRS preferred name) that differs from the child compound name.

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Compound Screening 108